HealthPolicy change

US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious

Published 6d ago · Updated 5d ago

Covered in 3 countries

AI summary38s readMixed

Grail's multi-cancer screening blood test secured cautious backing from FDA advisers despite lingering concerns over its clinical effectiveness.

An independent advisory panel for the Food and Drug Administration has granted tepid support to Grail's multi-cancer blood test following a scheduled vote. Committee members raised significant concerns regarding the test's overall effectiveness and clinical benefits. This regulatory scrutiny follows setbacks for the product after it previously failed a study conducted in the United Kingdom earlier in the year.

Grail states that its Galleri blood test is capable of detecting up to fifty different forms of cancer.
The FDA advisory panel expressed reservations about the overall benefits provided by the screening product.
The cancer-screening test previously failed a clinical study in the United Kingdom earlier in the year.

Written from 2 of 3 outlets — 1 has since joined this story.

By the numbers

50forms of cancer

Why it matters

Regulatory evaluation of multi-cancer early detection blood tests represents a critical milestone for oncology diagnostics and patient screening technologies.